 | | Anno I – Numero 9 | Comitato scientifico editoriale: Emilio Bria, Giuseppe Viscardi
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | | | Pubblicazioni 2025 |
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Background: Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival remains poor. In this study, we aimed to compare lurbinectedin plus atezolizumab and atezolizumab alone as maintenance therapies in patients with ES-SCLC without progression after induction therapy with atezolizumab, carboplatin, and etoposide … Continua a leggere
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
Background: HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.
Methods: We conducted an open-label, multicenter, multicohort, phase 1-2 study to evaluate sevabertinib at a twice-daily dose of 20 mg in patients with locally advanced or metastatic HER2-mutant NSCLC … Continua a leggere
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Background: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known … Continua a leggere
|
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
Background: Adagrasib is a KRASG12C inhibitor that demonstrated promising activity against KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to compare the efficacy and safety of adagrasib versus docetaxel in patients with KRASG12C-mutated advanced NSCLC previously treated with chemotherapy and immunotherapy … Continua a leggere
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
Background: Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study … Continua a leggere
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Introduction: Earlier results from the phase 3 EMPOWER-Lung 1 trial indicated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for patients with advanced NSCLC with programmed cell death-ligand 1 (PD-L1) expression in 50% or more tumor cells and no EGFR, ALK, or ROS1 aberrations. Here, we report the five-year outcomes … Continua a leggere
|
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported … Continua a leggere
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
Background: The phase III CheckMate 9LA study demonstrated durable overall survival (OS) benefit with nivolumab plus ipilimumab with chemotherapy versus chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Here, we report final, 6-year efficacy and safety outcomes … Continua a leggere
|
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Background: Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non-small-cell lung cancer (NSCLC) in a phase 3 trial. Data are needed on overall survival.
Methods: In this open-label, phase 3 trial, patients with stage IB to IIIA resectable NSCLC … Continua a leggere
|
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
The phase II PHAROS study previously showed that encorafenib plus binimetinib has antitumor activity in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (mNSCLC). In PHAROS, 98 patients (59 treatment-naïve; 39 previously treated) received encorafenib 450 mg once daily …Continua a leggere
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
Background: The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed …Continua a leggere
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
Background: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy …Continua a leggere
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Background: Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with advanced squamous NSCLC … Continua a leggere
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study
Background: ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival (OS), duration of response (DOR) and long-term safety data … Continua a leggere
| | Videointervista |
Le novità emerse nel 2025 sul carcinoma polmonare | Alessandro Morabito
Clicca qui per vedere la videointervista
| | Appuntamenti | Il percorso di cura dei pazienti affetti da neoplasie ginecologiche ed urologiche
Bari, 13 dicembre 2025
PROMOZIONE DELLA SALUTE, ECOLOGIA SOCIALE E FIBROMIALGIA
Selargius (CA), 13 dicembre 2025
Nasopharyngeal Carcinoma in Non-Endemic Area: Challenges, Advances, and Perspectives
Milano, 15 dicembre 2025
Ricerca e clinica nel tumore mammario: un binomio vincente al servizio delle pazienti
Bari, 15 dicembre 2025
Lung Cancer – Cocktail With Science
Milano / online, 15 dicembre 2025
AIOM Workshop on Clinical Research Methodology
Webinar, 15 dicembre 2025 dalle 17.00 alle 18.20
Immunoterapia sottocute nel paziente oncologico: più valore al tempo
Bagno a Ripoli (FI), 16 dicembre 2025
Prospettive Condivise nella Gestione del Carcinoma Mammario: Dialoghi tra Breast Unit
Brescia, 23 maggio – 16 dicembre 2025
ITALIANI AD ESMO 2025
I mercoledì dell’oncologia
Webinar non ECM, 17 dicembre 2025 dalle 17.00 alle 18.15
Siamo davvero ad un aut-aut?
Webinar, 22 dicembre 2025 dalle 17.00 alle 18
Carcinoma delle vie biliari avanzato: nuove prospettive terapeutiche
I mercoledì dell’oncologia
Webinar non ECM, 21 gennaio 2026 dalle 17.00 alle 18.15
Questi e altri appuntamenti si possono consultare sul sito AIOM: aiom.it
| © 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 3888896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
Iniziativa realizzata con il supporto non condizionante di
|
|
|
|
|